Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD), with its high prevalence, mortality, and disability rates and poor treatment response, not only seriously affects patient quality of life but also imposes large societal burdens.[@CIT0001] COPD is heterogeneous and is mainly characterized by respiratory symptoms, although there are also extrapulmonary effects, such as malnutrition[@CIT0002],[@CIT0003] and muscle dysfunction.[@CIT0004] The prognosis of patients with COPD is affected by multiple factors, such as the patients' symptoms, nutritional status,[@CIT0005] exercise tolerance[@CIT0006] and muscle function.[@CIT0004] A multidimensional evaluation is therefore needed.

The Body mass index, airflow Obstruction, Dyspnea, and Exercise (BODE) index, proposed by Celli et al[@CIT0007] as a multidimensional assessment, is widely used to evaluate COPD.[@CIT0008] It consists of the body mass index (BMI), airflow obstruction (forced expiratory volume in one second/the predicted value (FEV~1~%)), dyspnea (measured by the modiﬁed Medical Research Council (mMRC) scale), and exercise capacity (measured by the six-minute--walk test (6MWT)).[@CIT0007] Compared with spirometry or the ABCD assessment tool from the Global Initiative for Chronic Obstructive Lung Disease (GOLD),[@CIT0009] the BODE index more comprehensively reflects the characteristics of COPD by evaluating the patient's disease manifestations, nutrition, exercise, and pulmonary function and better predicts mortality[@CIT0010] and hospitalization.[@CIT0001] It is a pioneering tool for the multidimensional comprehensive assessment of COPD.

However, limitations still exist in the BODE index. First, in the BODE, FEV~1~% is classified according to the three stages identified by the American Thoracic Society (ATS), which is based on a spirometry test and can not directly reflect the severity of the disease.[@CIT0011] However, the GOLD classification system is associated with the severity of COPD[@CIT0012] and its cut-off values tend to be simpler. Furthermore, nutrition is an important factor that affects the prognosis of patients with COPD,[@CIT0013] and the mortality rate is lower in overweight patients than in normal-weight or low-weight patients.[@CIT0014] Among patients with COPD, weight loss mainly results from the loss of skeletal muscle.[@CIT0013] Muscle atrophy in COPD is caused by dyspnea, inadequate nutritional intake, insufficient exercise, and inflammation.[@CIT0015] The fat-free mass index (FFMI)[@CIT0016] has been shown to be better than BMI for assessing the nutritional status of patients with COPD.[@CIT0005] Finally, in addition to limb muscle weakness, respiratory muscle dysfunction is also frequently observed. Inspiratory muscle weakness is not only an important cause of acute exacerbation[@CIT0017] but also a significant predictor of death in patients with COPD.[@CIT0018] However, the BODE index does not include any indicator of respiratory muscle function.

In summary, this study aimed to develop a new index by modifying the BODE index and verifying the ability of the modified index to predict the mortality of patients with COPD to provide a new tool for clinicians when evaluating patients with COPD.

Materials and methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

From January 1, 2013 to January 1, 2014, 326 outpatients (63 females) with COPD were recruited from Zhujiang Hospital for this prospective cohort study. The inclusion criteria were as follows: age ≥40 years and diagnosis of COPD according to spirometry (FEV~1~/FVC\<0.70 after inhaling 400 µg of salbutamol aerosol). All patients were clinically stable and received appropriate therapy. Patients with bronchial asthma, advanced tuberculosis, bronchiectasis, severe cardiovascular disease, malignant tumors and those who had suffered a respiratory infection in the previous 4 weeks or participated in a rehabilitation program in the previous 3 months were excluded.

Data collection {#S0002-S2002}
---------------

The data collected at the baseline from all patients include age; sex; pack-years of smoking; pulmonary function, BMI, FFMI, mMRC, 6MWT, maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), exacerbations in the previous year and COPD assessment test (CAT) score.

Spirometry was performed with a spirometer (Pony FX229; Cosmed, Rome, Italy) at intervals of 20 mins before and after inhalation of 400 μg of salbutamol aerosol.[@CIT0019] The collected parameters of pulmonary function included forced vital capacity (FVC), forced expiratory volume in 1 s (FEV~1~), FEV~1~/FVC and FEV~1~%. The predicted values of FEV~1~ and FVC are calculated by using ECSC regression equations with appropriate conversion factors.[@CIT0020]

FFMI was measured with multifrequency electrodes (Inbody720; Biospace, Seoul, Korea). Each patient was measured twice and the average was calculated and used in subsequent analyses. BMI was calculated using the following formula: body mass/(height)^2^ (kg/m^2^). FFMI was calculated using the following formula: fat-free body mass/(height)^2^ (kg/m^2^).

The 6MWT was conducted under the supervision of an experienced clinician. During the test, the oxygen saturation level was maintained at above 90%. The tests were performed twice with an interval of at least 1 hr between the two tests. The maximum test result was used in the subsequent analyses.

MIP and MEP were assessed with a digital manometer (AZ-8205; AZ Instruics, Taiwan). Quality control was conducted according to the ATS and the European Respiratory Society (ERS) protocols, and the maximum value out of three measurements was selected.[@CIT0021]

Follow-up {#S0002-S2003}
---------

Subjects were followed every 3 months for at least 2 years or until death. Acute exacerbations requiring hospital management (emergency visits or admissions), if any, were recorded during the follow-up. The follow-up methods included telephone calls, clinic appointments and home visits. Subjects who were lost to follow-up were excluded from the analysis. One researcher identified and recorded the cause of death listed on the hospital record.

Written informed consent was obtained from all subjects. The protocol, which was in accordance with the Declaration of Helsinki, was approved by the ethics committee of Zhujiang Hospital, Southern Medical University, Guangzhou.

Identification of factors predicting mortality {#S0002-S2004}
----------------------------------------------

Univariate Cox regression was used to identify the factors that signiﬁcantly predicted mortality. The variables included were age, sex, pack-years of smoking, FVC, FEV~1~, FEV~1~/FVC, FEV~1~%, BMI, FFMI, 6MWT, mMRC score, MIP, MEP and number of exacerbations in the previous year. Those factors that were statistically significant were included in multivariate Cox regression.

Construction of FODEP, the new index {#S0002-S2005}
------------------------------------

The following modifications were made to the BODE index: (1) the reclassification of lung function according to the GOLD guidelines; (2) the substitution of the FFMI for BMI; and (3) the addition of MIP. The newly constructed index was named the FODEP index.

The FODEP index scores range from 0 to 15, as shown in [Table 1](#T0001){ref-type="table"}. According to the classification of airflow limitation based on the GOLD guidelines,[@CIT0012] the threshold for FEV~1~% ranged from 0 to 3. The value of FFMI ranged from 0 (FFMI ≥21.7 kg/m^2^ for males or FFMI ≥18.2 kg/m^2^ for females) to 3 (FFMI ≤16.6 kg/m^2^ for males or FFMI ≤14.5 kg/m^2^ for females), based on the ATS statement.[@CIT0022] As recommended,[@CIT0023] a MIP\>60 cmH~2~O is considered normal. The value of MIP was 0 when MIP was \>60 cmH~2~O; otherwise, it was 3. The ranges of mMRC and 6MWT were the same as in the BODE index.Table 1Construction of the fat-free mass index, degree of airflow obstruction, Dyspnea, exercise capacity, and maximal inspiratory pressure (FODEP) index and the number of subjects in each of the 4 stages for each component of the FODEP indexVariables/N0123FEV~1~% (%)/N≥80/3150--79/14630--49/108\<30/416MWT (m)/N≥350/251250--349/41150--249/25≤149/9mMRC/N0--1/1512/883/554/32FFMI (kg/m^2^)/NFor males≥21.7/519.8--21.6/1216.7--19.7/99≤16.6/148For females≥18.2/416.8--18.1/1014.6--16.7/31≤14.5/17MIP (cmH~2~O)/N\>60/140≤60/186[^2]

Verification of the FODEP index {#S0002-S2006}
-------------------------------

A receiver operating characteristic (ROC) curve analysis was performed to compare the abilities of the BODE index and the FODEP index to predict mortality in patients with COPD. Patients were categorized into quartiles according to their FODEP scores. Then, Kaplan--Meier curves were plotted for all four groups to compare the differences in survival among the groups.

Statistical analysis {#S0002-S2007}
--------------------

Continuous variables are presented as the mean ± SD, unless otherwise stated. Associations between factors and mortality were evaluated using Cox regression. ROC curve analysis was performed to compare the overall performances of the FODEP index and the BODE index with regard to the prognostic prediction and to determine the optimal threshold. Kaplan--Meier curves were constructed to determine the differences in survival among patients grouped according to their FODEP score quartile. Pearson correlation analysis was used to evaluate the relationship between FODEP and hospitalization. *P*\<0.05 was considered statistically signiﬁcant. Except for the ROC curve analyses, which were performed with MedCalc Statistical Software version 15.2.2 (MedCalc Software, Ostend, Belgium), all other analyses were conducted with SPSS v. 20 (IBM Corporation, Armonk, NY, USA).

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

In total, 502 patients were initially enrolled, of whom 121 patients were excluded. Then, the remaining 381 patients were followed until the end of the study or death, while 55 patients were lost to follow-up. Thus, 326 patients (63 females; median age: 67.6 years \[range: 41--92 years\]) were included in the analysis ([Figure 1](#F0001){ref-type="fig"}). In this study, patients were followed for a median of 34 months (range: 1--59 months). The baseline characteristics of the survivors and nonsurvivors are shown in [Table 2](#T0002){ref-type="table"}. During follow-up, 19 subjects (5.8%) died in the first 24 months, and 48 (14.7%) died in the first 59 months. [Figure 2](#F0002){ref-type="fig"} shows the change in mortality of the subjects in two different periods. The majority of patients (56 percent) died of respiratory failure, 15 percent died of cardiogenic shock, 10 percent of cerebrovascular accident, and the rest of miscellaneous causes.Table 2Baseline characteristics of 277 survivors and 48 nonsurvivorsBaseline characteristicsSurvivors\
(n=277)Nonsurvivors\
(n=48)*P*-valueFemale/Male56/2218/40Age66.87±10.4271.81±9.30\<0.01Pack-years smoked24.67±28.8624.35±22.860.943BMI (kg/m^2^)22.26±3.8021.36±3.570.129FFMI (kg/m^2^)16.53±2.33414.32±2.01\<0.001FEV~1~ (L)1.31±0.551.09±0.51\<0.05FEV~1~% (%)54.89±19.3433.65±13.10\<0.001FVC (L)2.49±0.832.19±0.78\<0.05FEV~1~/FVC52.91±12.2050.41±13.090.195mMRC1.54±1.043.00±1.24\<0.0016MWT (m)436.70±105.26327.00±127.74\<0.001MIP (cmH~2~O)59.17±19.3841.67±12.21\<0.001CAT15.23±7.6219.71±8.70\<0.001Exacerbations in the previous year0.93±1.101.33±1.260.041[^3][^4] Figure 1Flow chart of the study.**Note:** We excluded such patients who were at acute episode at the time of enrollment, accompanied by more severe dyspnea and other symptoms, for they were unable to take the lung function test and six-minute-walk test in this study.Figure 2FODEP scores and mortality rates over time. For each unit of the FODEP score, the bars show the proportion of subjects alive and dead at the end of 24 months and 59 months.

Identiﬁcation of factors predicting mortality {#S0003-S2002}
---------------------------------------------

Univariate Cox analysis suggested that the following factors were significantly associated with mortality ([Table 3](#T0003){ref-type="table"}): age, FFMI, FEV~1~%, mMRC score, 6MWT distance, MIP, FEV~1~, FVC, MEP, and the number of exacerbations in the previous year. Interestingly, the association between BMI and mortality was not significant (*P*=0.069). Incorporating the above factors into multivariate Cox analysis revealed that the following factors were still significantly associated with mortality ([Table 4](#T0004){ref-type="table"}): FFMI (*P*=0.001), FEV1% (*P*\<0.001), mMRC score (*P*=0.025), 6MWT distance (*P*=0.001), and MIP (*P*=0.001).Table 3Univariate Cox regression analysis of independent predictors of death in COPD patientsPredictorBHR (95% CI)*p*-valueSex0.2311.259 (0.589, 1.693)0.552Age0.0521.054 (1.021, 1.088)0.001Pack-years smoked0.0031.003 (0.993, 1.013)0.595FFMI (kg/m^2^)−0.3830.681 (0.605, 0.767)\<0.001BMI (kg/m^2^)−0.740.929 (0.857, 1.006)0.069FEV~1~% (%)−0.0830.920 (0.898, 0.943)\<0.001mMRC0.9452.574 (1.925, 3.441)\<0.0016MWT (m)−0.0070.993 (0.991, 0.995)\<0.001FEV~1~ (L)−0.7840.457 (0.254, 0.822)0.009FVC (L)−0.4160.659 (0.458, 0.950)0.025FEV~1~/FVC−0.0180.982 (0.960, 1.004)0.110Number of exacerbations in the previous year0.2491.283 (1.019, 1.615)0.034MIP (cmH~2~O)−0.0540.948 (0.930, 0.966)\<0.001MEP (cmH~2~O)−0.220.978 (0.964, 0.992)0.002[^5] Table 4Multivariate Cox regression analysis of independent predictors of mortality in COPD patientsPredictorBHR (95% CI)*p*-valueFFMI (kg/m^2^)−0.2680.765(0.657,0.891)0.001FEV~1~% (%)−0.0490.952(0.929,0.975)\<0.001FEV~1~ (L)0.5961.815(0.502,6.559)0.36FVC (L)0.1551.168(0.545,2.505)0.69Number of exacerbations in the previous year−0.0530.948(0.710,1.226)0.72Age−0.0060.994(0.957,1.032)0.74mMRC0.3401.404(1.050,1.878)0.026MWT (m)−0.0060.994(0.990,0.997)0.001MEP (cmH~2~O)0.0121.012(0.991,1,034)0.259MIP (cmH~2~O)−0.0460.955(0.928,0.982)0.001[^6]

Evaluation of the ability of the FODEP index to predict mortality {#S0003-S2003}
-----------------------------------------------------------------

The ROC curves for the BODE index and the FODEP index are shown in [Figure 3](#F0003){ref-type="fig"}. The AUCs for the BODE index and the FODEP index were 0.778 (95% CI: 0.729--0.822) and 0.860 (95% CI: 0.817--0.896), respectively. The AUC of the FODEP index was significantly different from that of the BODE index (*P*\<0.001 by Delong's method).[@CIT0024] The Youden index of the FODEP index was 0.577, with a sensitivity and specificity of 81.25% and 76.45%, respectively. The Youden index for the BODE index was 0.427, with a sensitivity and specificity of 72.92% and 69.78%, respectively.Figure 3ROC curves of the BODE and FODEP index for the prediction of mortality in COPD patients.**Note:** The AUC of FODEP: 0.860 (95% CI: 0.817--0.896), BODE: 0.778 (95% CI: 0.729--0.822). Difference of ROC curves was significant between FODEP and BODE (*P*\<0.001 by Delong et al (1988)).[@CIT0024]

Patients were categorized into quartiles according to their FODEP scores as follows: 0--4, 5--8, 9--12, and 13--15. The Kaplan-Meier curves are presented in [Figure 4](#F0004){ref-type="fig"}. The survival rate decreased as the FODEP index increased; the association was more significant with a higher FODEP index (*P*\<0.001 by the log-rank test).Figure 4Kaplan-Meier survival curves for patients stratified by quartiles of FODEP scores.**Note:** Quartile 1: scores of 0 to 4; Quartile 2: scores of 5 to 8; Quartile 3: scores of 9 to 12; Quartile 4: scores of 13 to 15. Survival differed signiﬁcantly among the 4 groups: *P*\<0.01 by the log rank test.

Correlation between the FODEP index and the number of hospitalizations {#S0003-S2004}
----------------------------------------------------------------------

The FODEP index has a moderate correlation with the number of hospitalizations (r=0.384, *P*\<0.001). However, as shown in [Figure 5](#F0005){ref-type="fig"}, the ROC curves showed there was no significant difference in predicting the risk of rehospitalization between the BODE index and the FODEP index (*P*=0.7046). The AUC of the FODEP index was 0.632 (95% CI: 0.577--0.684), and the AUC of the BODE index was 0.624 (95% CI: 0.569 −0.677). The Youden index of the FODEP index was 0.238, with a sensitivity and specificity of 72.12% and 51.69%, respectively. The Youden index of the BODE index was 0.186, with a sensitivity and specificity of 63.46% and 55.08%, respectively.Figure 5ROC curves of the BODE and FODEP indexes for the prediction of the risk of COPD-related hospitalization.**Note:** The AUC of FODEP: 0.632(95% CI: 0.577--0.684), BODE: 0.624 (95% CI: 0.569 −0.677). Difference of ROC curves was not significant between FODEP and BODE (*P*=0.7046 by Delong et al (1988)).[@CIT0024]

Discussion {#S0004}
==========

This study has shown that the FODEP index, consisting of FFMI, FEV~1~%, the mMRC score, the 6MWT distance and MIP, is a signiﬁcant and independent predictor of mortality, with every one point increase in the FODEP index score associated with a 1.55-fold increased risk of death.

Univariate Cox regression showed that age, FFMI, FEV~1~%, mMRC score, 6MWT distance, MIP, FEV~1~, FVC, MEP, and the number of exacerbations in the previous year were independent predictors of the risk of mortality in COPD patients; these findings were in line with the results of other studies such as DOSE,[@CIT0025] which indicated that smoking status and exacerbation frequency (as well as dyspnea and airﬂow obstruction) were important predictive factors, or ADO,[@CIT0026] which included age (plus dyspnea and airﬂow obstruction). However, we found that only five factors (FFMI, FEV~1~%, mMRC score, 6MWT distance and MIP) were still significantly correlated with mortality in the multivariate Cox regression, which is the reason those variable were chosen for inclusion in the FODEP index.

BMI was used to assess nutritional status in the BODE index; however, it does not reflect the status of skeletal muscle in patients with COPD.[@CIT0027] Compared with BMI, FFMI seems to be more related to muscle atrophy, exercise capacity, and quality of life. FFMI was also found to be a predictor of overall mortality in subjects with normal BMI.[@CIT0028] Thus, replacing BMI with FFMI could more accurately reflect the nutritional status of COPD patients.

Inspiratory muscle strength is commonly reduced in COPD patients, and the degree of reduction is related to the severity of disease.[@CIT0015] Previous studies reported that respiratory muscle weakness is observed in 20--50% of patients, with the reduction ranging from 15% to 30%.[@CIT0029] In 2010, Hill et al[@CIT0023] proposed that respiratory muscle strength is closely linked to dyspnea and exercise capacity. Inspiratory muscle strength, as assessed by MIP, has been shown to be an independent predictor of survival in COPD patients,[@CIT0018] which was consistent with the findings of this study. In addition, as it is less affected by external factors, MIP provides a convenient metric for inspiratory strength. Therefore, MIP was included in the FODEP index.

The ROC curve suggests that the FODEP index may be a better predictor of mortality than the BODE index, although it remains to be confirmed by further study. Kaplan-Meier survival analysis revealed that the FODEP score was closely related to the risk of mortality in patients with COPD, and the cumulative survival rate of patients with the highest FODEP score was significantly lower than that of patients with lower scores.

Exacerbations of COPD are key events in COPD management,[@CIT0030] making exacerbation frequency a marker of disease severity.[@CIT0031] Preventing exacerbations of COPD, especially hospitalizations, is a major goal in the management of patients with COPD. Previous studies have suggested that the BODE index is a better predictor of hospitalization for COPD than is GOLD staging based on FEV~1~,[@CIT0001] while our study suggested that the FODEP index has a similar ability to predict COPD-related hospitalization as that of the BODE index. Thus, the FODEP index may be helpful in predicting hospitalizations in COPD patients.

This study has certain limitations. The cohort was relatively small, and the observation duration was not long enough. Second, previous studies have shown that image-based COPD classifications can indicate degrees of dyspnea and acute exacerbations.[@CIT0032] Van Tho et al suggested that COPD patients with different phenotypes on imaging examinations may present with different clinical manifestations.[@CIT0032] However, imaging-based phenotypes of COPD were not included in the multidimensional indicators in this study.

Conclusion {#S0005}
==========

Compared with the BODE index, the FODEP index is better able to predict the prognosis of COPD patients. Moreover, the FODEP index provides further insights into the comprehensive assessment and management of COPD patients.
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